GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (XSWX:NOVNEE) » Definitions » Cyclically Adjusted PB Ratio

Novartis AG (XSWX:NOVNEE) Cyclically Adjusted PB Ratio : 3.29 (As of May. 26, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Novartis AG Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Novartis AG's current share price is CHF91.75. Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was CHF27.86. Novartis AG's Cyclically Adjusted PB Ratio for today is 3.29.

The historical rank and industry rank for Novartis AG's Cyclically Adjusted PB Ratio or its related term are showing as below:

XSWX:NOVNEE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.23   Med: 2.77   Max: 3.5
Current: 3.29

During the past years, Novartis AG's highest Cyclically Adjusted PB Ratio was 3.50. The lowest was 2.23. And the median was 2.77.

XSWX:NOVNEE's Cyclically Adjusted PB Ratio is ranked worse than
70.66% of 692 companies
in the Drug Manufacturers industry
Industry Median: 1.89 vs XSWX:NOVNEE: 3.29

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novartis AG's adjusted book value per share data for the three months ended in Mar. 2024 was CHF17.278. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is CHF27.86 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted PB Ratio Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.14 2.94 2.79 2.81 3.04

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.79 3.00 3.16 3.04 3.13

Competitive Comparison of Novartis AG's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PB Ratio falls into.



Novartis AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novartis AG's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=91.75/27.86
=3.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novartis AG's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=17.278/107.3549*107.3549
=17.278

Current CPI (Mar. 2024) = 107.3549.

Novartis AG Quarterly Data

Book Value per Share CPI Adj_Book
201406 25.990 101.517 27.485
201409 27.633 101.247 29.300
201412 28.774 100.704 30.674
201503 30.919 100.339 33.081
201506 30.397 100.464 32.482
201509 31.138 99.785 33.500
201512 32.297 99.386 34.887
201603 29.587 99.475 31.931
201606 29.500 100.088 31.642
201609 30.720 99.604 33.111
201612 32.132 99.380 34.711
201703 28.613 100.040 30.705
201706 28.891 100.285 30.928
201709 30.033 100.254 32.160
201712 31.588 100.213 33.839
201803 28.917 100.836 30.787
201806 32.753 101.435 34.664
201809 32.670 101.246 34.641
201812 33.739 100.906 35.895
201903 20.343 101.571 21.501
201906 22.170 102.044 23.324
201909 22.975 101.396 24.325
201912 24.066 101.063 25.564
202003 21.336 101.048 22.668
202006 22.364 100.743 23.832
202009 21.916 100.585 23.391
202012 22.280 100.241 23.861
202103 20.924 100.800 22.285
202106 21.933 101.352 23.232
202109 23.418 101.533 24.761
202112 27.880 101.776 29.408
202203 25.850 103.205 26.889
202206 27.969 104.783 28.656
202209 27.520 104.835 28.182
202212 26.082 104.666 26.752
202303 22.976 106.245 23.216
202306 22.571 106.576 22.736
202309 16.703 106.570 16.826
202312 19.744 106.461 19.910
202403 17.278 107.355 17.278

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis AG  (XSWX:NOVNEE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novartis AG Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (XSWX:NOVNEE) Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (XSWX:NOVNEE) Headlines

No Headlines